VAN ORGO is different and interesting! It is the same company I bought many moons ago for their surgical glue but they then went private! And recently re emerged!!!! Need some cash so I'm worried about a secondary!
The company finished the quarter with $46.9 million in cash on hand.Organogenesis returned to public trading at the beginning of last year, after 16 years as a private company. Like many high-tech medical companies, it has not yet turned a profit – but it does have exciting prospects for successful products in potentially lucrative sales fields.This potential lies behind 5-star analyst Richard Newitter’s comments. In his report for Leerink, Newitter writes, “As a relatively new public company, we believe ORGO has yet to be fully “discovered” by investors with a below-peer valuation that in our view is highly dislocated from the company’s longer-term sales growth prospects, healthy end-markets, and a scalable long term 70%+ GM business.
I don't getthat GM as in General Motors? Or does that stand for Glue Something...
Ultimately, as investors increasingly come to appreciate ORGO’s potential for sustainable DD top-line growth & increased profitability prospects into the out-years, we think the multiple will expand driving shares higher.”In line with his upbeat outlook, Newitter rates ORGO shares a Buy, and his $7 price target implies a 112% upside potential. In short, the analyst believes that now is the time for investors to get in at the ground level.
The company finished the quarter with $46.9 million in cash on hand.Organogenesis returned to public trading at the beginning of last year, after 16 years as a private company. Like many high-tech medical companies, it has not yet turned a profit – but it does have exciting prospects for successful products in potentially lucrative sales fields.This potential lies behind 5-star analyst Richard Newitter’s comments. In his report for Leerink, Newitter writes, “As a relatively new public company, we believe ORGO has yet to be fully “discovered” by investors with a below-peer valuation that in our view is highly dislocated from the company’s longer-term sales growth prospects, healthy end-markets, and a scalable long term 70%+ GM business.
I don't getthat GM as in General Motors? Or does that stand for Glue Something...
Ultimately, as investors increasingly come to appreciate ORGO’s potential for sustainable DD top-line growth & increased profitability prospects into the out-years, we think the multiple will expand driving shares higher.”In line with his upbeat outlook, Newitter rates ORGO shares a Buy, and his $7 price target implies a 112% upside potential. In short, the analyst believes that now is the time for investors to get in at the ground level.